Y-mAbs Therapeutics pulls back 11 percent this week, but still delivers shareholders decent 90 percent return over 1 year
YMAB Stock | USD 5.19 0.37 6.65% |
About 79 percent of Y MAbs' investors are selling. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that quite a large number of traders are terrified. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Some Y-mAbs Therapeutics, Inc. shareholders are probably rather concerned to see the share price fall...
Read at simplywall.st
![]() |
Y MAbs Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Y MAbs is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
STRO | Sutro Biopharma | 0.00 |
| ||
PCVX | Vaxcyte | 0.00 |
| ||
SNDX | Syndax Pharmaceuticals | 1.02 |
| ||
EWTX | Edgewise Therapeutics | 2.45 |
| ||
MIRM | Mirum Pharmaceuticals | 3.32 |
| ||
MRUS | Merus BV | 3.44 |
| ||
BLUE | Bluebird Bio | 4.90 |
| ||
BDTX | Black Diamond | 4.98 |
| ||
KRON | Kronos Bio | 5.61 |
| ||
RVMD | Revolution Medicines | 5.89 |
| ||
ARQT | Arcutis Biotherapeutics | 6.28 |
| ||
ERAS | Erasca | 6.57 |
| ||
GBIO | Generation Bio | 6.90 |
| ||
ZNTL | Zentalis Pharmaceuticals | 7.25 |
| ||
TVTX | Travere Therapeutics | 7.48 |
| ||
MRSN | Mersana Therapeutics | 7.69 |
| ||
PASG | Passage Bio | 7.69 |
| ||
DAWN | Day One | 8.94 |
| ||
CCCC | C4 Therapeutics | 11.44 |
| ||
LRMR | Larimar Therapeutics | 12.54 |
|
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |